Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer

PURPOSE: We tested the hypothesis that Akt-Ser473 phosphorylation (pAkt) predicts benefit from the sequential addition of paclitaxel to adjuvant doxorubicin plus cyclophosphamide (AC) chemotherapy in patients with node-positive breast cancer participating in the National Surgical Adjuvant Breast and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Yang, Sherry X., Costantino, Joseph P., Kim, Chungyeul, Mamounas, Eleftherios P., Nguyen, Dat, Jeong, Jong-Hyeon, Wolmark, Norman, Kidwell, Kelley, Paik, Soonmyung, Swain, Sandra M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2010
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903333/
https://ncbi.nlm.nih.gov/pubmed/20479407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.1602
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi